Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GERN vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: GERN 3 – 3 XOMA Matrix Metrics: GERN 2 – 8 XOMA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Geron Corp (GERN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). GERN carries a Unified Composite Score of 60.8/100 (BUY) at $0.95 (51.0x Forward P/E, -7.2% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Composite vs. Pillar Nuance: While GERN currently prints a higher short-term Unified Composite Score (60.8/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -7.2% operating margin) and revenue trajectory (-22.6% vs. +27.4% YoY).
  • Technical & Structure Timing Caution: GERN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GERN vs XOMA
GERN NASDAQ
Geron Corp
Pharmaceutical Preparations
$0.95
-2.06% 1D
Market Cap $640.4M
TTM Revenue $218M
Forward P/E 51.0x
Beta / 30D Vol 1.52β · 101% Vol
Unified Composite Score
60.8 / 100 BUY
Tech 69.0 Fund 70.0 Flow 71.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $1.03 · SMA50: $1.17
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (GERN 3 – 3 XOMA)

Columns: Metric · GERN · XOMA
1. Valuation Multiples XOMA
Forward P/E 51.0x 21.5x
Trailing P/E 51.0x 28.2x
PEG Ratio N/M N/M
EV / Revenue 3.2x 16.1x
2. Growth & Scale GERN
Revenue Growth (YoY) +27.4% -22.6%
Earnings Growth (YoY) +0.0% +207.9%
TTM Revenue (USD) $218M $49M
Market Cap $640.4M $781.8M
3. Profitability & Quality XOMA
Gross Margin 62.5% 99.0%
Operating Margin -7.2% -3.9%
Net Profit Margin -22.0% 69.6%
Return on Equity (ROE) -20.1% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) -$91M $8.3M EBITDA
Cash Flow Margin -41.9% 17.1% EBITDA Mgn
Net Cash / Leverage $52M Net Debt (0.53x D/E) $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GERN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 86.2% (15th %ile) 101.5% (100th %ile)
Put/Call OI Skew 3.06x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat GERN
OpEx & R&D Intensity 69.7% of Rev ($152M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GERN (2) vs XOMA (8)
Institutional Metric GERN XOMA Criterion Row Edge
Market Capitalization
Scale
$640.4M $781.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
51.0x 28.2x Lower Multiple XOMA
Forward P/E Ratio
Valuation
51.0x 21.5x Lower Multiple XOMA
Revenue Growth (YoY)
Growth
+27.4% -22.6% Higher Growth GERN
Operating Margin (TTM)
Profitability
-7.2% -3.9% Higher Margin XOMA
Net Profit Margin
Profitability
-22.0% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
-20.1% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
9% ($1–$2) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
1.52β · 101% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
60.8 / 100 (BUY) 55.8 / 100 (HOLD) Higher Composite GERN
Trailing 12M Revenue (USD)
Operating Scale
$218M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
62.5% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$91M ($52M Net Debt (0.53x D/E)) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GERN +32.9 pp
GERN: +29.09% · XOMA: -3.81%
3M Horizon XOMA +24.31 pp
GERN: -14.97% · XOMA: +9.34%
6M Horizon XOMA +30.61 pp
GERN: +3.65% · XOMA: +34.26%
1Y Horizon XOMA +1.12 pp
GERN: +23.48% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GERN vs XOMA. Trailing 12-month operating profitability (GERN -7.2% vs XOMA -3.9%) and valuation multiples (GERN 51.0x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

GERN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$218M
Gross Margin62.5%
Op. Margin-7.2%
ROE / Fwd P/E-20.1% · 51.0x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GERN BREAKDOWN
72d in phase · OBV NEUTRAL
Current IV 86.2%
IV Percentile 15th %ile
Put/Call OI Skew 3.06x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact GERN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GERN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $640.4M market capitalization and -7.2% operating margin.
OpEx & R&D Reinvestment 69.7% of Rev ($152M)
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GERN vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Geron Corp (GERN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). GERN carries a Unified Composite Score of 60.8/100 (BUY) at $0.95 (51.0x Forward P/E, -7.2% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Composite vs. Pillar Nuance: While GERN currently prints a higher short-term Unified Composite Score (60.8/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -7.2% operating margin) and revenue trajectory (-22.6% vs. +27.4% YoY). Technical & Structure Timing Caution: GERN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GERN leads the Growth & Scale pillar: GERN posts +27.4% YoY revenue growth and +0.0% YoY earnings growth on $218M TTM revenue (62.5% gross margin, -7.2% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, GERN generates $218M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, GERN deploys 69.7% of Rev ($152M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

XOMA screens cheaper on headline valuation multiples. GERN trades at 51.0x Forward P/E, 51.0x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-41.9% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GERN (-20.1% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GERN carries 86.2% implied volatility (15th %ile, Compressed (<25th %ile)), a 3.06x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 101% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.